CAS Number54573-75-0
Synonyms(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; doxercalciferol; MFCD01076571; Hectorol
Molecular FormulaC28H44O2
Molecular Weight412.65
Purity98.00%
Density1.0±0.1 g/cm3
Boiling Point538.7±50.0 °C at 760 mmHg
Melting Point138-140ºC
AppearanceWhite crystalline powder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 54573-75-0 |
| Catalog No. | 2A-9044229 |
| Chinese Name | 度骨化醇 |
| Synonyms | (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; doxercalciferol; MFCD01076571; Hectorol |
| Molecular Formula | C28H44O2 |
| Molecular Weight | 412.65 |
| Purity | 98.00 |
| Density | 1.0±0.1 g/cm3 |
| Boiling Point | 538.7±50.0 °C at 760 mmHg |
| Melting Point | 138-140ºC |
| Appearance | White crystalline powder |
| Storage Condition | Desiccate at -20°C |
| Application | Doxercalciferol is a vitamin D2 analog and a vitamin D (Vitamin D) receptor activator that can counteract the progression of kidney disease. |
| PubChem ID | 329798592 |
| SMILES | C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC(C)C(C)C)CC(O)CC1O |
| InChI | InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1 |
| InChI Key | HKXBNHCUPKIYDM-XXZMWSRPSA-N |
| Hazard Symbols | transportation |
| Bioactivity | Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease. Related Catalog Signaling Pathways >> Vitamin D Related >> VD/VDR Research Areas >> Metabolic Disease Target Vitamin D receptor[1] In Vivo Doxercalciferol (0.083, 0.167 or 0.333 μg/kg, i.p.) elevates serum phosphorus at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol (0.167 and 0.333 μg/kg) also increases serum calcium and Ca × P at Weeks 2 and 6, and enhances increased pulse wave velocity (PWV) at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol blocks PTH from rising at 0.083 μg/kg, and lowers serum PTH to the SHAM level[1]. Doxercalciferol (125 ng/kg, i.p. thrice per week) increases expression of VDR mRNA level and renal expression of TRPV5 in NON mice fed a HF diet. Doxercalciferol also improves proteinuria, prevents loss of podocytes, and accumulation of extracellular matrix proteins in HF diet-induced mice. Doxercalciferol inhibits the expression of profibrotic growth factors (TGF-β, PAI-1, and connective tissue growth factor (CTGF)), and blocks increased expression of the renin-angiotensin-aldosterone system in mice fed a HF diet. Furthermore, Doxercalciferol suppresses macrophage infiltration, decreases NF-κb activity, and preventes expression of proinflammatory cytokine and the increase in renal lipid accumulation in mice fed a HF diet[2]. Doxercalciferol (30 ng/kg, i.p. thrice per week) prevents albuminuria, markedly attenuates podocyte loss and apoptosis, and reduces glomerular fibrosis in streptozotocin-induced diabetic mice[3]. Animal Admin Rats[1] Male, Sprague-Dawley, 5/6 nephrectomized (NX) rats (∼200 gm) are used 1 week after nephrectomy. The nephrectomy is performed using a standard two-step surgical ablation procedure. Beginning 2 weeks post-nephrectomy, rats are maintained on a high phosphorus diet (0.9% phosphorus and 0.6% calcium) for the duration of the study to induce secondary hyperparathyroidism. On Day 0, SHAM and 5/6 NX rats (n = 7-10 per group) receive vehicle (5% EtOH/95% propylene glycol; 0.4 mL/kg; i.p.) or VDRA (paricalcitol or Doxercalciferol; 0.083, 0.167 or 0.333 μg/kg; intraperitoneally) three times per week for 41 days (n = 6-10 per group). These doses are chosen based on the fact that lower doses (0.021 and 0.042 μg/kg; i.p.) of either compound are not PTH suppressive after 2 or 6 weeks of treatment in this model of CKD. On Days 0, 13 and 41, blood is collected (24 h post-dose). On Days 0, 13 and 41 (24 h post-dose), animals are anaesthetized with ketamine (50 mg/kg) and blood is collected via the tail vein for PTH and serum blood chemistry determinations[1]. References [1]. Noonan W, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008 Dec;23(12):3824-30. [2]. Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10. [3]. Wang Y, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86. Chemical & Physical Properties Density 1.0±0.1 g/cm3 Boiling Point 538.7±50.0 °C at 760 mmHg Melting Point 138-140ºC Molecular Formula C28H44O2 Molecular Weight 412.648 Flash Point 224.0±24.7 °C Exact Mass 412.334137 PSA 40.46000 LogP 8.15 Vapour Pressure 0.0±3.3 mmHg at 25°C Index of Refraction 1.541 InChIKey HKXBNHCUPKIYDM-XXZMWSRPSA-N SMILES C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC(C)C(C)C)CC(O)CC1O Storage condition Desiccate at -20°C |
| Use of | Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease. Properties Articles27 Name 1α-Hydroxy Vitamin D2 Synonym More Synonyms Doxercalciferol Biological Activity Description Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease. Related Catalog Signaling Pathways >> Vitamin D Related >> VD/VDR Research Areas >> Metabolic Disease Vitamin D receptor[1] References [1]. Noonan W, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008 Dec;23(12):3824-30. [2]. Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10. [3]. Wang Y, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86. Chemical & Physical Properties Molecular Formula C28H44O2 Exact Mass 412.334137 PSA 40.46000 Index of Refraction 1.541 InChIKey HKXBNHCUPKIYDM-XXZMWSRPSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Doxercalciferol) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Doxercalciferol) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Doxercalciferol) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Nizofenone | 54533-85-6 | 2A-9044222 |
| 2-(2-Ethoxyethoxy)ethyl bromide | 54550-36-6 | 2A-9044223 |
| 2-Phenyl-2-imidazoline pyromellitate | 54553-90-1 | 2A-9044224 |
| Pyromellitic acid di(2-phenyl-2-imidazoline) salt | 54553-91-2 | 2A-9044225 |
| Propiverine hydrochloride | 54556-98-8 | 2A-9044226 |
| 2-[4-(Dibutylamino)-2-hydroxybenzoyl]benzoic acid | 54574-82-2 | 2A-9044230 |
| D-Allylglycine | 54594-06-8 | 2A-9044233 |
| 2-Ethoxythiophenol | 54615-63-3 | 2A-9044238 |
| 2,3,5-Tri-O-benzyl-D-ribose | 54623-25-5 | 2A-9044241 |
| 2-(4-Fluorophenoxy)nicotinic acid | 54629-13-9 | 2A-9044243 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS